Drug intelligence / Profile preview

mefenamate

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Mefenamate is the carboxylate anion and active species derived from **mefenamic acid**, a fenamate nonsteroidal anti-inflammatory drug. In pharmacology and medicinal chemistry literature, \"mefenamate\" often refers specifically to the deprotonated ligand form present in salts and metal complexes, while in vivo the clinically used drug is mefenamic acid. Its principal therapeutic biology is inhibition of cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby producing analgesic, anti-inflammatory, and antipyretic effects; fenamates have also been reported to modulate certain ion channels and, in experimental systems, mefenamate has been linked to cochlear NMDA receptor-mediated tinnitus biology indirectly through cyclooxygenase inhibition and altered arachidonic acid signaling. The provided sources mainly describe mefenamate as a chemical ligand or counterion in complexes, salts, and delivery materials rather than as a standalone proprietary development candidate.

Other names
mefenamatemefenamic acid anion
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on mefenamate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mefenamate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call